Can Celcuity (CELC) Climb 87.59% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 09/10/24
Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/14/24
Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference CallGlobeNewsWire • 08/07/24
Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt FinancingGlobeNewsWire • 05/30/24
Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/15/24
Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference CallGlobeNewsWire • 05/08/24
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/27/24
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference CallGlobeNewsWire • 03/20/24
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer SymposiumGlobeNewsWire • 12/06/23
Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer SymposiumGlobeNewsWire • 12/01/23
Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 11/13/23